Morishita Hiroki, Otsuka Ryota, Toyozumi Takeshi, Matsumoto Yasunori, Sekino Nobufumi, Okada Koichiro, Shiraishi Tadashi, Kamata Toshiki, Iida Shinichiro, Makiyama Tenshi, Nishioka Yuri, Yamada Masanari, Matsubara Hisahiro
Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Cancer Diagn Progn. 2024 Nov 3;4(6):762-768. doi: 10.21873/cdp.10393. eCollection 2024 Nov-Dec.
BACKGROUND/AIM: Identifying prognostic and molecular markers as therapeutic targets for esophageal squamous cell carcinoma (ESCC) could enhance the efficacy of multidisciplinary treatments. While tissue expression of sirtuin 1 (SIRT1) has been linked to tumor progression in ESCC, prognostic significance of serum SIRT1 levels and their correlation with tissue SIRT1 remains unexplored. This study aimed to investigate the correlation between serum and tissue SIRT1 levels in patients with ESCC.
A total of 38 patients diagnosed with ESCC who were untreated preoperatively were recruited for this study. SIRT1 expression in the surgical specimens was assessed through immunostaining, while serum SIRT1 levels were measured using an enzyme-linked immunosorbent assay. We analyzed the association between tissue and serum SIRT1 levels, clinicopathological features, and patient prognosis.
Positive SIRT1 expression in tissue was significantly associated with deeper tumor depth (p=0.020). It was also significantly associated with poorer overall survival (OS) and relapse-free survival (RFS) (p=0.041 and p=0.012, respectively). Elevated serum SIRT1 levels were significantly correlated with increased tumor depth and weight loss (p=0.012 and p=0.030). While higher serum SIRT1 levels tended to be associated with poorer OS (p=0.069), no significant correlation was found between SIRT1 expression in tissue and its concentration in serum.
SIRT1 tissue expression may be a valuable prognostic marker in ESCC. However, the clinical significance of serum SIRT1 levels appears to differ from that of its tissue expression. Future research is required to clarify the role of serum SIRT1 in ESCC.
背景/目的：鉴定作为食管鳞状细胞癌（ESCC）治疗靶点的预后和分子标志物可提高多学科治疗的疗效。虽然沉默调节蛋白1（SIRT1）的组织表达与ESCC的肿瘤进展有关，但血清SIRT1水平的预后意义及其与组织SIRT1的相关性仍未得到探索。本研究旨在探讨ESCC患者血清和组织SIRT1水平之间的相关性。
本研究共纳入38例术前未经治疗的ESCC确诊患者。通过免疫染色评估手术标本中SIRT1的表达，同时采用酶联免疫吸附测定法测量血清SIRT1水平。我们分析了组织和血清SIRT1水平、临床病理特征与患者预后之间的关联。
组织中SIRT1阳性表达与肿瘤深度增加显著相关（p = 0.020）。它还与较差的总生存期（OS）和无复发生存期（RFS）显著相关（分别为p = 0.041和p = 0.012）。血清SIRT1水平升高与肿瘤深度增加和体重减轻显著相关（p = 0.012和p = 0.030）。虽然血清SIRT1水平较高往往与较差的OS相关（p = 0.069），但未发现组织中SIRT1表达与其血清浓度之间存在显著相关性。
SIRT1组织表达可能是ESCC中有价值的预后标志物。然而，血清SIRT1水平的临床意义似乎与其组织表达不同。未来需要进一步研究以阐明血清SIRT1在ESCC中的作用。
Zotero 插件